Brief: Silence Therapeutics PLC Says Cash And Cash Equivalents Of £73.5 Mln Is Sufficient To Fund Operations Through Early 2023
March 17 (Reuters) - Silence Therapeutics PLC SLNCF.PK :
* SILENCE THERAPEUTICS PLC - BELIEVES CASH AND CASH
EQUIVALENTS OF
£73.5 MILLION AS OF END OF DEC 2021 IS SUFFICIENT TO FUND
OPERATIONS THROUGH EARLY 2023
Source text for Eikon: ID:nBw4x9P9pa
Further company coverage: SLNCF.PK
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing